Suven will present the key biology data in animal models of cognition and brain microdialysis on SUVN-502, a potent, selective brain penetrant and orally active 5-HT6 receptor antagonist for the symptomatic treatment of Alzheimer's disease.
The company's scientists will also present a paper on new animal model for Alzheimer's disease with dual blockade of cholinergic and glutametertic neural system induced memory impairment in rats, according to a press release on Monday.
Alzheimer's disease has a significant unmet medical need for which current treatment options are insufficient.
Suven has a number of discovery programmes in te area of cognition, focusing on novel approaches that may lead to the development of new therapies for patients, the release added.
